Home
Products
DrugLnk Products
Drug-linker Complexes
SGD-1910 (Mc-Val-Ala-PBD )

SGD-1910 (Mc-Val-Ala-PBD ) (CAT#: ADC-S-027)

Linker-Toxin SET, this set is made by Pyrrolobenzodiazepine (PBDs) conjugated to the lysosomally cleavable dipeptide, valine-alanine (va) linker. PBDs are a class of DNA-crosslinking agents that are significantly more potent than systemic chemotherapeutic drugs.

Product Information

CAS NO
1342820-51-2

Description
Linker-Toxin SET, this set is made by Pyrrolobenzodiazepine (PBDs) conjugated to the lysosomally cleavable dipeptide, valine-alanine (va) linker. PBDs are a class of DNA-crosslinking agents that are significantly more potent than systemic chemotherapeutic drugs.

Molecular Weight
1089.20

Purity
95%

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-S-027. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

Excellent quality

Using SGD-1910 (Mc-Val-Ala-PBD) in our drug discovery projects yielded impressive anti-tumor effects. The linker-toxin combination is highly efficient, with targeted action and minimal off-target toxicity.

Excellent

SGD-1910 (Mc-Val-Ala-PBD) provided by Creative Biolabs was extremely effective in our cell-based assays. Its potent DNA crosslinking ability allowed us to achieve significant cell death in cancer cells.

Excellent

The use of SGD-1910 (Mc-Val-Ala-PBD) has significantly boosted our targeted therapy studies. The PBD's potency and the cleavable linker make it an excellent choice for studying DNA damage response mechanisms.

Excellent

SGD-1910 (Mc-Val-Ala-PBD) showed high efficacy in inducing apoptosis in our cancer models. Its design allows for precise targeting, making it an outstanding candidate for cancer drug development. Creative Biolabs delivered it with excellent purity and consistency.

Excellent

We've had great success with SGD-1910 (Mc-Val-Ala-PBD) in our DNA-targeted therapies. The linker-toxin combination offers superior potency, and Creative Biolabs ensured the product met all of our quality standards.

Q: 1: What is the mechanism of action of SGD-1910 (Mc-Val-Ala-PBD)?
A: SGD-1910 (Mc-Val-Ala-PBD) functions as a potent DNA cross-linking agent, disrupting cancer cell proliferation by targeting DNA replication. The Mc-Val-Ala linker ensures specific delivery to the target cells, enhancing therapeutic efficacy.
Q: 2: What is the mechanism of action of SGD-1910 in antibody-drug conjugates (ADCs)?
A: SGD-1910 utilizes a cleavable Mc-Val-Ala linker to release the PBD toxin upon entering cancer cells. The PBD agent then induces potent DNA crosslinking, leading to cell death, enhancing ADC efficacy.
Q: 3: How is SGD-1910 (Mc-Val-Ala-PBD) synthesized?
A: SGD-1910 (Mc-Val-Ala-PBD) is synthesized through a controlled chemical process, involving conjugation of a peptide-based linker (Mc-Val-Ala) to the PBD warhead. The linker ensures selective delivery and the PBD moiety induces potent DNA cross-linking.
Q: 4: What is the recommended dosage for SGD-1910 (Mc-Val-Ala-PBD) in preclinical studies?
A: Dosage recommendations for SGD-1910 (Mc-Val-Ala-PBD) in preclinical models vary depending on the cancer type and study design. Typically, the dosage is calibrated based on body weight and tumor burden in the animal models.
Q: 5: What are the potential side effects of SGD-1910 (Mc-Val-Ala-PBD) in animal studies?
A: Common side effects observed in animal studies of SGD-1910 (Mc-Val-Ala-PBD) include mild weight loss and hematological changes. However, the specificity of its mechanism helps minimize off-target toxicity.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.